Compare EB & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EB | BNTC |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.7M | 405.7M |
| IPO Year | 2018 | N/A |
| Metric | EB | BNTC |
|---|---|---|
| Price | $4.43 | $10.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.00 | ★ $28.25 |
| AVG Volume (30 Days) | ★ 2.7M | 224.5K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $294,798,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.81 | $9.70 |
| 52 Week High | $4.46 | $17.15 |
| Indicator | EB | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 84.03 | 32.40 |
| Support Level | $2.44 | $12.78 |
| Resistance Level | $4.46 | $12.99 |
| Average True Range (ATR) | 0.02 | 0.95 |
| MACD | 0.04 | -0.10 |
| Stochastic Oscillator | 98.77 | 21.07 |
Eventbrite Inc is a self-service ticketing and experience technology platform that serves event creators. The company's two-sided marketplace connects creators and consumers every month to share their passions, artistry, and causes through live experiences. Creators use its self-service ticketing and marketing tools to plan, promote, and sell tickets to their events, and event seekers use its website and mobile application to discover and purchase tickets to experiences. Geographically, it generates maximum revenue from the United States. The company generates revenues principally from service fees and payment processing fees from the sale of paid tickets on its platform.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.